Ajanta Pharma has launched the product in two strengths, 20 mg and 40 mg tablets," Ajanta Pharma said in a BSE filing. Eletriptan hydrobromide tablets, the company said is a part its growing portfolio of products developed for the US market.
In total, Ajanta has 35 Abbreviated New Drug Applications (ANDAs) of which it has 19 final ANDA approvals, two tentative approvals, and 14 ANDAs under review with US FDA. So far it has launched 14 products in the US market.
Shares of Ajanta Pharma were trading 0.35 per cent higher at Rs 1,197.10 on the BSE.
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)